Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 614-295-4 | CAS number: 68131-40-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics
- Data waiving:
- study scientifically not necessary / other information available
- Justification for data waiving:
- other:
Reference
Description of key information
No toxicokinetic study has been conducted. data from physicochemical properties and in vivo toxicity tests have been used to predict the toxicokinetics of Softanol 30.
There is limited evidence that the test substance is absorbed via the gastrointestinal tract and some absorption via the skin or lungs cannot be ruled out if exposure occurs. There is also evidence of some systemic distribution to the liver. There is no evidence of metabolism or metabolic fate. Excretion via the kidney is considered to be the major route of excretion based on the molecular weight of Softanol 30 (without taking into account phase 2 metabolism) and supporting evidence from other alcohol ethoxylates whereas biliary excretion is considered possible based on a slight increase in liver weight. The liver and kidneys may be sites of metabolism. There was no information on bioaccumulation.
Key value for chemical safety assessment
Additional information
No specific study was performed on the absorption/distribution/metabolism/excretion (ADME) of this substance (Softanol 30) but data are currently available from the physico-chemical and in vivo toxicology studies. Softanol 30 is not a single chemical structure but a series of closely related C11-15 secondary alcohol ethoxylates differing by chain length. The substance is a UVCB with high purity (100%). The physicochemical properties are very similar between the different chain lengths because of the closeness of the homologues. The similarity between the properties of the homologues in the mixture enables a prediction of toxicokinetics to be made which applies to the entire UVCB. Studies specifically conducted on other alcohol ethoxylates to determine toxicokinetics have been reported (HERA, 2009) and provide a useful addition to available evidence.
Absorption
Oral route The physico-chemical characteristics of Softanol 30 suggest that the substance will be well absorbed via the gastro-intestinal tract. Its molecular weight is small at 334 (MW< 500), its Log P value is high (Log P = approximately 6.0) and its solubility in water is moderate at 1.1 mg/L. The high logP value may suggest low oral absorption by the Lipinski rule (Lipinski et al, 2001). There were no deaths but there were non-specific clinical signs of toxicity in the acute oral study. In the repeated dose studies in rats test treated with Softanol 30 there were transient effects on body weight, increased liver weights and disturbances in clinical biochemistry, but no target organ toxicity. In the developmental toxicity study low body weight, food consumption and low fetal body weights were the only effects of the test material. There was no evidence of direct systemic toxicity. With little evidence of direct systemic toxicity but non-specific signs of general toxicity it is difficult to confirm significant absorption by the gastrointestinal tract. It is likely that some absorption does occur as evidenced by the increased liver weight and disturbances in clinical biochemistry parameters. A study conducted by Unilever (1978) and reviewed by HERA (2009) showed that orally intubated 14C12AEx alcohol ethoxylates was extensively absorbed and excreted via the urine in rats. There was little difference between the oral, intraperitoneal and subcutaneous routes. Dermal route Softanol is a liquid with a MW of 334 and a Log P value of >6.0. Its solubility in water is 1.1 mg/L at 20°C. A substance in a liquid state with MW of circa 300 and a high Log P value possibly suggests low dermal absorption. The substance must be sufficiently soluble in water to partition from the stratum corneum into the epidermis. Between 1-100 mg/L absorption is anticipated to be low to moderate. Softanol 30 physico-chemical properties indicate that it might not be well absorbed through the skin, and there was no evidence of a systemic effect in the acute dermal toxicity study thus providing circumstantial evidence of low absorption. Softanol 30 is classified as a skin sensitiser based on in vivo data, suggesting sufficient dermal absorption to elicit a response. This is supported by evidence of local erythema and scales on the back of rats in an acute dermal toxicity study. In vivo studies reviewed by HERA (2009) showed that a variety of dermally applied 14C alcohol ethoxylates were well-absorbed through the skin. The detail of those studies is not available but the reviewers consistently support significant dermal absorption. The HERA (2009) review also discusses human dermal absorption data for C12AE6 which shows that human skin is more resistant to dermal absorption than rat skin. In light of the above and in view of the fact that there are no specific data on C11-15 secondary alcohol ethoxylates, it is considered not possible to provide a quantitative estimate of human dermal absorption. Inhalation route With a vapour pressure of 0.013 Pa at 25°C and boiling temperature is >280°C, Softanol 30 is not a highly volatile substance and therefore not likely to be available for inhalation as a vapour, however no inhalation study is available to investigate absorption via the inhalation route.
Distribution
The findings from the oral acute and repeated dose studies provide limited evidence that the test substance is distributed systemically when absorbed by the gastrointestinal tract. In the acute oral toxicity study there were no deaths at 2000 mg/kg. In the repeated dose study there was evidence of systemic distribution to the liver (higher liver weights and lower total bilirubin). There was no evidence of systemic distribution after dermal application. There is no evidence of distribution to the fetus since there was no adverse effect on survival but exposure cannot be ruled out.
Metabolism
No data are available on metabolism in the existing toxicity studies. There was limited evidence of an effect on tissues with high metabolism capability (increased liver weight) which could have provided evidence for metabolism.
Excretion
Molecular weight of Softanol 30 is relatively low (334 average) and absorbed small organic compounds are more likely to be excreted in the urine. Data from the HERA review (2009) support the urine as the major excretory route for alcohol ethoxylates, irrespective of the route of exposure. Biliary excretion is more likely for high molecular weight compounds either because of biotransformation by phase 2 conjugation or because the parent is innately large (>500 MW).
Conclusion
There is limited evidence that the test substance is absorbed via the gastrointestinal tract and some absorption via the skin or lungs cannot be ruled out if exposure occurs. There is also evidence of some systemic distribution to the liver. There is no evidence of metabolism or metabolic fate. Excretion via the kidney is considered to be the major route of excretion based on the molecular weight of Softanol 30 (without taking into account phase 2 metabolism) and supporting evidence from other alcohol ethoxylates whereas biliary excretion is considered possible based on a slight increase in liver weight. The liver and kidneys may be sites of metabolism. There was no information on bioaccumulation.
References HERA (2009) Human and Environmental Risk Assessment on ingredients of European household cleaning products: Alcohol Ethoxylates v2 Lipinski, CA, Lombardo, F, Dominy, BW and Feeney, PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46, 3-26
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.